"Building on the introduction of BD's 4mm needle and 5-bevel PentaPoint Comfort design, we are confident that our new EasyFlow Technology will provide the most comfortable injection experience to help enable patients to adhere more easily to their therapy regimens and ultimately improve their outcomes," said Linda Tharby, President, BD Medical – Diabetes Care.
BD's steady pace of patient friendly enhancements has caught the attention of some important audiences. For example, BD Ultra-Fine Nano 4mm Pen Needles with EasyFlow Technology have earned the Arthritis Foundation Ease-of-Use Commendation, which recognizes products proven to make life easier for people who have arthritis and other physical limitations. Independently tested by experts and evaluated by people with arthritis, EasyFlow Technology was commended for ease of use when attaching, injecting, and dispensing medication on select insulin pens for people with dexterity challenges.
EasyFlow Technology is currently available in the U.S. and Canada on all BD Ultra-Fine Nano 4mm Pen Needles with PentaPoint Comfort and will be available in many European countries in the coming months. For more information on how EasyFlow Technology and other BD innovations can help improve outcomes for people with diabetes, visit www.bd.com/nano
About Diabetes Diabetes is a disease in which the body has a shortage of insulin or a decreased ability to use insulin, a hormone that allows glucose (sugar) to enter cells and be converted to energy. When diabetes is not controlled, glucose and fats remain in the blood and, over time, damage vital organs. Diabetes has become a national health concern in the United States, with an estimated 26 million people - 8.3 percent of the population - living with the disease. Of those people, an estimated 18.8 million have been diagnosed with diabetes, and another 7 million are thought to be undiagnosed. If current trends continue, as many as one in three U.S. adults will have diabetes by 2050. The total annual cost of diagnosed diabetes in the United States is an estimated $245 billion.For nearly 90 years, BD's culture of innovation and continuous improvement has enhanced the patient experience to help improve therapy and outcomes for people with diabetes worldwide. BD devices support earlier initiation and better adherence to prescribed therapies to help all diabetes patients live healthier lives.